The cost of the weight-loss drug Mounjaro, often dubbed the 'King Kong' jab, will not be as high as initially feared, following commercial deals struck between its manufacturer, Eli Lilly, and private providers. Earlier this month, Eli Lilly had announced plans to more than double wholesale prices from September 1, with the highest dose set to increase from £122 to £330 a month, and mid-range doses like the 5mg pen from £92 to £180. However, documents reveal that these new arrangements will cap the top dose at £247.50, almost £100 less than the proposed list price, with similar smaller discounts applied to lower strengths. Eli Lilly confirmed these commercial arrangements aim to maintain affordability, expecting them to benefit patients when the price changes take effect. Despite these efforts, the initial announcement sparked significant panic among slimmers, leading many to stockpile months' worth of Mounjaro pens to avoid the higher costs. This 'Covid-style' panic buying has reportedly caused some pharmacies to run out of stock and led to a temporary pause in Mounjaro supply to the UK by Lilly, to prevent further stockpiling at current lower prices.

The price hike and subsequent panic have also raised serious concerns about patients turning to the black market. Experts fear that reduced-price, illicit jabs could put patients' health at severe risk. Between June 2024 and June 2025, Border Force at Heathrow seized over 18,000 illegal weight-loss and diabetes medications, including counterfeit Ozempic and Mounjaro pens, with smugglers found hiding fake pens on their bodies. Health officials have repeatedly warned about dangerous fake weight loss jabs containing toxic ingredients, which have led to severe illness and even fatalities in some cases.

Adding to the complexity, the phased NHS rollout of Mounjaro, intended for the most severely unwell patients, has been plagued by inconsistencies and a 'postcode lottery' of provision. While the government aims to tackle the UK's obesity crisis—which costs the NHS over £11 billion annually and the economy billions more—less than half of England's commissioning bodies have begun prescribing the drug since its June rollout. Data gathered by the British Medical Journal (BMJ) reveals that only nine out of 42 Integrated Care Boards (ICBs) had funding for at least 70 percent of their eligible patients, with some, like Coventry and Warwickshire, funding as little as 21 percent. This deficit in funding, despite clear health needs, has been criticized by health leaders, who advocate for greater clarity and adequate budgets, particularly in more deprived areas with higher demand.

Patients like Julia Dore, 51, and Jenny Lloyd, 50, illustrate the agonizing dilemma faced by many who self-funded Mounjaro treatment. Having successfully lost significant weight—Julia shed five-and-a-half stone and improved multiple health conditions, while Jenny lost almost five stone and saw her diabetes go into remission—they found themselves ineligible for NHS prescriptions. The strict official guidelines for NHS Mounjaro prescription require a Body Mass Index (BMI) over 40 (or 30-34.9 with specific referral criteria) and at least one weight-related health problem. Both Ms. Dore and Ms. Lloyd, after losing weight, no longer met these criteria. Shockingly, their doctors suggested they would need to regain weight to qualify for an NHS prescription, a prospect described as 'soul-destroying' and medically dangerous, risking the return of serious health issues like high blood pressure and diabetes.

Professor Naveed Sattar of the University of Glasgow acknowledged the phased introduction of the drug on the NHS was justified to target high-risk patients and save money, but conceded that the health service did not anticipate so many people self-funding and then being caught in this bind. Professor David Strain of the University of Exeter Medical School argues for greater flexibility, suggesting that patients who initially self-funded and would have been eligible at the start should have their prescriptions taken over by the NHS. For those unable to secure an NHS prescription or afford rising private costs—which could see annual outlays jump from £1,500 to nearly £3,000 for some—alternatives exist. Switching to other GLP-1 drugs like Wegovy, which may be cheaper, or focusing on lifestyle changes such as a fibre-rich diet and increased physical activity, can help maintain weight loss. Future changes in prescribing rules are anticipated, with criteria potentially relaxing from next year, but the NHS warns it could take up to 12 years for all four million eligible individuals to receive treatment. New drugs like retatrutide and the oral orforglipron are also in clinical trials, promising greater competition and potentially lower prices in the future. Until then, many patients like Ms. Dore feel unsupported by a system that has left them in a difficult position, caught between life-changing treatment and escalating costs.